G2TT
来源类型Research Report
规范类型报告
Medicaid Prescriptions for Extended-Release Medications to Treat Opioid Use Disorder
Lisa Clemans-Cope; Emma Winiski; Marni Epstein; Luis E. Basurto
发表日期2020-04-14
出版年2020
语种英语
概述Extended-release prescription medications to treat opioid use disorder (MOUDs) offer long-acting, first-line treatment options for people with opioid use disorder (OUD). These long-acting medications could help retain more people in treatment and help people manage their day-to-day lives successfully—an even more urgent issue in light of the coronavirus pandemic. Three extended-release MOUDs—Vivitrol, Probuphine
摘要

Extended-release prescription medications to treat opioid use disorder (MOUDs) offer long-acting, first-line treatment options for people with opioid use disorder (OUD). These long-acting medications could help retain more people in treatment and help people manage their day-to-day lives successfully—an even more urgent issue in light of the coronavirus pandemic. Three extended-release MOUDs—Vivitrol, Probuphine, and Sublocade—have entered the market in recent years, but there is little information about how many Medicaid enrollees receive long-acting MOUD across state Medicaid programs and what the net cost is for Medicaid after adjusting for federal rebates. We analyze Medicaid State Drug Utilization Data from 2011 to 2018 and find the following:

  • Medicaid enrollees rarely receive extended-release buprenorphine (Probuphine and Sublocade), but use of extended-release naltrexone (Vivitrol) is extensive.
  • Our estimates of the federal rebates from manufacturers lowered states’ net drug costs substantially in 2018. Adjusting for federal rebates, cost per prescription decreased from $1,206 to $589 for Vivitrol, from $1,522 to $1,147 for Sublocade, and from $2,650 to $2,038 for Probuphine. Accounting for these rebates may improve the cost effectiveness of extended-release MOUDs.

Additionally, in light of the coronavirus pandemic and related barriers to and risks of face-to-face interaction and daily or frequent office visits, health care providers and Medicaid patients on short-acting MOUDs could consider whether extended-release treatments provide more stable medication therapy.

This report is part of a larger project, Tracking Medicaid-Covered Prescriptions to Treat Opioid Use Disorder. Click here to learn more.

This report was updated April 15, 2020, to remove "per 1,000 Medicaid enrollees" from the title of figure 3 (page 12); the title now correctly describes the total numbers of Sublocade prescriptions across the US in 2018 by state quartile.

主题Health and Health Policy
URLhttps://www.urban.org/research/publication/medicaid-prescriptions-extended-release-medications-treat-opioid-use-disorder
来源智库Urban Institute (United States)
资源类型智库出版物
条目标识符http://119.78.100.153/handle/2XGU8XDN/480966
推荐引用方式
GB/T 7714
Lisa Clemans-Cope,Emma Winiski,Marni Epstein,et al. Medicaid Prescriptions for Extended-Release Medications to Treat Opioid Use Disorder. 2020.
条目包含的文件
文件名称/大小 资源类型 版本类型 开放类型 使用许可
medicaid-prescriptio(1517KB)智库出版物 限制开放CC BY-NC-SA浏览
个性服务
推荐该条目
保存到收藏夹
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Lisa Clemans-Cope]的文章
[Emma Winiski]的文章
[Marni Epstein]的文章
百度学术
百度学术中相似的文章
[Lisa Clemans-Cope]的文章
[Emma Winiski]的文章
[Marni Epstein]的文章
必应学术
必应学术中相似的文章
[Lisa Clemans-Cope]的文章
[Emma Winiski]的文章
[Marni Epstein]的文章
相关权益政策
暂无数据
收藏/分享
文件名: medicaid-prescriptions-for-extended-release-medications-to-treat-opioid-use-disorder.pdf
格式: Adobe PDF
此文件暂不支持浏览

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。